Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.
The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.
The Chinese Academy of Sciences-led team said the approach could lead to a therapeutic strategy for human aneuploidy diseases involving additional chromosomes.
In a study involving almost 23,000 women, DNA reflex testing detect 95 percent of trisomies while avoiding recalls.
Denmark-based Arcedi would like to commercialize its technology through a major diagnostic company.
Several commercial NIPT providers in the US said they are planning to participate in the new program.
The company says Panorama is the only NIPT that can tell whether twins are identical or fraternal, which can impact the clinical management of a pregnancy.
Under the terms of the deal, Dahui Biotech will distribute Devyser's prenatal aneuploidy diagnostic test kits in China.
A UCLA group and spinout FetoLumina Technologies are working on a clinical assay for noninvasive prenatal diagnostics.
At a conference last week, researchers from Italy presented results from 73 women who had mosaic embryos transferred.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.